469 related articles for article (PubMed ID: 29970059)
1. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D
Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
BMC Musculoskelet Disord; 2018 Jul; 19(1):210. PubMed ID: 29970059
[TBL] [Abstract][Full Text] [Related]
2. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
Zhang ZL; Liao EY; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; De Peng Y; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L; Santora AC
Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
Liao EY; Zhang ZL; Xia WB; Lin H; Cheng Q; Wang L; Hao YQ; Chen DC; Tang H; Peng YD; You L; He L; Hu ZH; Song CL; Wei F; Wang J; Zhang L
Medicine (Baltimore); 2018 Aug; 97(31):e11694. PubMed ID: 30075569
[TBL] [Abstract][Full Text] [Related]
4. Alendronate/vitamin D3 70 mg/2800 IU with and without additional 2800 IU vitamin D3 for osteoporosis: results from the 24-week extension of a 15-week randomized, controlled trial.
Binkley N; Ringe JD; Reed JI; Ljunggren O; Holick MF; Minne HW; Liu M; Lamotta A; West JA; Santora AC
Bone; 2009 Apr; 44(4):639-47. PubMed ID: 19185560
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
Ralston SH; Binkley N; Boonen S; Kiel DP; Reginster JY; Roux C; Chen L; Rosenberg E; Santora A;
Calcif Tissue Int; 2011 Jun; 88(6):485-94. PubMed ID: 21479913
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of weekly alendronate plus vitamin D₃ 5600 IU versus weekly alendronate alone in Korean osteoporotic women: 16-week randomized trial.
Kim KJ; Min YK; Koh JM; Chung YS; Kim KM; Byun DW; Kim IJ; Kim M; Kim SS; Min KW; Han KO; Park HM; Shin CS; Choi SH; Park JS; Chung DJ; Mok JO; Baek HS; Moon SH; Kim YS; Lim SK;
Yonsei Med J; 2014 May; 55(3):715-24. PubMed ID: 24719139
[TBL] [Abstract][Full Text] [Related]
7. Alendronate with and without cholecalciferol for osteoporosis: results of a 15-week randomized controlled trial.
Recker R; Lips P; Felsenberg D; Lippuner K; Benhamou L; Hawkins F; Delmas PD; Rosen C; Emkey R; Salzmann G; He W; Santora AC
Curr Med Res Opin; 2006 Sep; 22(9):1745-55. PubMed ID: 16968578
[TBL] [Abstract][Full Text] [Related]
8. Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens.
Minisola S; Cianferotti L; Biondi P; Cipriani C; Fossi C; Franceschelli F; Giusti F; Leoncini G; Pepe J; Bischoff-Ferrari HA; Brandi ML
Osteoporos Int; 2017 Nov; 28(11):3239-3249. PubMed ID: 28815282
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
Roux C; Binkley N; Boonen S; Kiel DP; Ralston SH; Reginster JY; Pong A; Rosenberg E; Santora A;
Calcif Tissue Int; 2014 Feb; 94(2):153-7. PubMed ID: 23912950
[TBL] [Abstract][Full Text] [Related]
10. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D status and response to daily 400 IU vitamin D3 and weekly alendronate 70 mg in men and women with osteoporosis.
Karaplis AC; Chouha F; Djandji M; Sampalis JS; Hanley DA
Ann Pharmacother; 2011 May; 45(5):561-8. PubMed ID: 21521859
[TBL] [Abstract][Full Text] [Related]
13. Effects of 25-hydroxyvitamin D3 therapy on bone turnover markers and PTH levels in postmenopausal osteoporotic women treated with alendronate.
Olmos JM; Hernández JL; Llorca J; Nan D; Valero C; González-Macías J
J Clin Endocrinol Metab; 2012 Dec; 97(12):4491-7. PubMed ID: 23043189
[TBL] [Abstract][Full Text] [Related]
14. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
15. Effect of alendronate and vitamin D₃ on fractional calcium absorption in a double-blind, randomized, placebo-controlled trial in postmenopausal osteoporotic women.
Shapses SA; Kendler DL; Robson R; Hansen KE; Sherrell RM; Field MP; Woolf E; Berd Y; Mantz AM; Santora AC
J Bone Miner Res; 2011 Aug; 26(8):1836-44. PubMed ID: 21448918
[TBL] [Abstract][Full Text] [Related]
16. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
17. Maintenance vitamin D3 dosage requirements in Chinese women with post menopausal osteoporosis living in the tropics.
Venugopal Y; Hatta SFWM; Musa N; Rahman SA; Ratnasingam J; Paramasivam SS; Lim LL; Ibrahim L; Choong K; Tan AT; Chinna K; Chan SP; Vethakkan SR
Asia Pac J Clin Nutr; 2017 May; 26(3):412-420. PubMed ID: 28429905
[TBL] [Abstract][Full Text] [Related]
18. Dose-response effects of supplementation with calcifediol on serum 25-hydroxyvitamin D status and its metabolites: A randomized controlled trial in older adults.
Vaes AMM; Tieland M; de Regt MF; Wittwer J; van Loon LJC; de Groot LCPGM
Clin Nutr; 2018 Jun; 37(3):808-814. PubMed ID: 28433267
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of cholecalciferol and calcitriol on calcium metabolism and bone turnover in Chinese postmenopausal women with vitamin D insufficiency.
Zhang H; Huang QR; Gu JM; Hu WW; Liu YJ; Hu YQ; Zhang ZL
Acta Pharmacol Sin; 2012 Apr; 33(4):490-5. PubMed ID: 22407227
[TBL] [Abstract][Full Text] [Related]
20. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
